-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, argenx announced that the US FDA approved the "first-in-class" therapy Vyvgart (efgartigimod alfa-fcab) for the treatment of anti-acetylcholine receptor (AChR) antibody-positive systemic myasthenia gravis (gMG) adult patients
Myasthenia gravis is a rare chronic autoimmune disease
Vyvgart is a "first-in-class" therapy targeting FcRn, designed to reduce pathogenic IgG antibodies and block the IgG recycling process
This approval is based on the results of the global Phase 3 clinical trial ADAPT, which was published in The Lancet Neurology in July this year
Reference materials:
[1] argenx Announces US Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis.
(The original text has been deleted)